Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

A 67-Year-Old Man With NTRK Fusion-Positive Metastatic Lung Cancer

home / case-based-peer-perspectives / a-67-year-old-man-with-ntrk-fusion-positive-metastatic-lung-cancer

Luis Raez, MD, reviews the case of a 67-year-old man with metastatic non-small cell NTRK gene fusion lung cancer.


Case of an NTRK Fusion-Positive Lung Cancer Patient

EP. 1: Case of an NTRK Fusion-Positive Lung Cancer Patient

Luis E. Raez, MD
April 22nd 2020

Watch


Testing in NTRK Fusion-Positive Lung Cancer

EP. 2: Testing in NTRK Fusion-Positive Lung Cancer

Luis E. Raez, MD
April 22nd 2020

Watch


Treatment in NTRK Fusion-Positive Lung Cancer

EP. 3: Treatment in NTRK Fusion-Positive Lung Cancer

Luis E. Raez, MD
April 22nd 2020

Watch


Targeted Treatment in NTRK Fusion-Positive Cancer

EP. 4: Targeted Treatment in NTRK Fusion-Positive Cancer

Luis E. Raez, MD
April 22nd 2020

Watch


Larotrectinib in NTRK Fusion-Positive Lung Cancer

EP. 5: Larotrectinib in NTRK Fusion-Positive Lung Cancer

Luis E. Raez, MD
April 22nd 2020

Watch


Response to Treatment With Larotrectinib

EP. 6: Response to Treatment With Larotrectinib

Luis E. Raez, MD
April 22nd 2020

Watch


Management of Toxicities of Larotrectinib

EP. 7: Management of Toxicities of Larotrectinib

Luis E. Raez, MD
April 22nd 2020

Watch


Treatment Resistance Due to Gene Mutation

EP. 8: Treatment Resistance Due to Gene Mutation

Luis E. Raez, MD
April 22nd 2020

Watch


Larotrectinib: A Tumor-Agnostic Therapy

EP. 9: Larotrectinib: A Tumor-Agnostic Therapy

Luis E. Raez, MD
April 22nd 2020

Watch

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.